Discover the top crypto presales of 2026 and see why IPO Genie tops analysts’ lists. Explore the hottest picks and what sets ...

Inside Jeff Brown SpaceX IPO review 2026, I have decoded Elon Musk’s AI Masterplan theory in detail so that you can take an informed decision.

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...

Jeremy Grantham has a new and provocative argument for why the U.S. stock market will produce mediocre returns this year. Grantham is the co-founder of GMO, the Boston-based investment firm. He has ...

Joseph Lucosky is the Managing Partner of Lucosky Brookman, a leading law firm in the world of microcap IPOs and Nasdaq/NYSE listings. For decades, getting listed on Nasdaq followed a simple formula.

As India’s first AI company to IPO, Fractal Analytics didn’t have a stellar first day on the public markets, as enthusiasm for the technology collided with jittery investors recovering from a major ...

OpenAI, Anthropic, and Databricks lead a new class of super-sized private companies eyeing public markets. The US IPO market has never seen a trillion-dollar debut. That may soon change as a wave of ...

On January 21, Lynn Martin, NYSE president, joined CNBC to discuss the IPO landscape for 2026. Martin predicted a super cycle for IPO activity this year. She noted that many companies are currently ...

The U.S. is poised for a wave of significant IPOs, with Goldman Sachs projecting proceeds to quadruple to a record $160 billion in 2026. The analysts also predicted that the number of IPOs will double ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After one Bay Area IPO got a ...

OpenAI’s latest funding round valued the company at $830B. Anthropic is currently valued at $350B with an enterprise and AI safety focus. SpaceX and xAI are combining for an IPO estimated at $1.25T in ...

Eikon Therapeutics is heading to the Nasdaq this morning with an upsized $381 million IPO in a further sign of the renewed appeal of the public markets. The oncology biotech will offer 21.2 million ...